1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

02 Feb 2023
Admin
News Article

Deka Biosciences Gets Us Fda Clearance For Dk210 (Egfr) Ind Application

Deka Biosciences (Deka), A Biotech Company Focused On Developing Novel Cytokine Therapies To Treat Cancer And Inflammatory Diseases, Announced That The Us Food And Drug Administration (Fda) Has Completed Its Review Of The Investigational New Drug (Ind) Application For Dk210 (Egfr) And Concluded That Deka May Proceed With A Phase 1 Clinical Trial In The United States.The Phase 1, First-In-Human, Multicenter Clinical Study Seeks To Characterize The Safety, And Biomarkers For Response Of Dk210 (Egfr) In Patients With Advanced Solid Cancer Who Are Overexpressing Epidermal Growth Factor Receptors (Egfr) (Nct05704985)."Obtaining Fda Clearance For Our Company'S First Programme To Start Clinical Trials Is A Significant Achievement," Said Dr. John Mumm, Ceo And Co-Founder Of Deka. "We Are Excited To Move Forward With The Clinical Development Of Dk210 (Egfr) And The Potential It Holds For Positively Impacting The Lives Of Many Cancer Patients."Dk210 (Egfr) Is The First Of Several Experimental Therapeutics Developed As Part Of Deka'S Platform Of Molecules. Each Diakine In Deka'S Platform Consists Of Two Cytokines Coupled Together Onto A Single Chain Variable Fragment Targeting System That Enables The Cytokines To Accumulate More Specifically Into Specific Tissues. The Combination Of The Two Cytokines Increases Potency And Reduces Toxicity While The Targeting System Also Improves The Drug'S Efficacy, Safety, And Manufacturability. Deka Has Identified Genetic Markers That Are Related To Responses To Each Diakine. These Markers Will Be Evaluated In Early Clinical Trials With The Hope Of Using Them As Potential Diagnostic Tools To Match Patients With The Most Effective Diakine Treatment In Later Stage Trials.Deka Biosciences Is A Biotech Company Led By Entrepreneur Dr. John Mumm, Who Is Backed By A Team Of Experienced Academic, Biopharma And Cdmo Innovators With Expertise In Drug Discovery, Product Development, Characterization, Testing And Clinical Development

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!